Registry for pediatric autoimmune and autoinflammatory diseases in China
Official title: Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Run by Peking Union Medical College Hospital · NCT06417502 · Data updated 2026-11-12
This study collects information from children in China with autoimmune and autoinflammatory diseases to better understand their conditions and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 18 Years |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 9 sites (Beijing, Beijing Municipality and 8 other locations) |
| Status | Recruiting |
| Started | April 29, 2022 |
| Main results expected | November 30, 2024 |
| Study ends | December 31, 2031 |
| Registry record updated | May 16, 2024 |
| Trial ID | NCT06417502 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 18 years or younger diagnosed with rheumatic and immunologic diseases in China.
✕Probably not a fit
Patients who do not have a diagnosed rheumatic or immunologic disease or those who are not treated in China may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects data on pediatric patients in China diagnosed with rheumatic and immunologic diseases. The study aims to explore various aspects such as clinical phenotypes, diagnoses, complications, drug safety, and therapeutic efficacy through a multi-center approach. Utilizing standardized data collection methods and a web-based platform, the registry captures real-world data without any intervention outside routine clinical practice. The goal is to enhance understanding and treatment of these conditions in the pediatric population.
Why it matters
Potential benefit: If successful, this registry could improve the understanding and management of pediatric autoimmune diseases, leading to better patient outcomes.
How similar studies have gone: Other observational registries have shown success in improving patient care and outcomes in similar conditions, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \<= 18 years old * Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity) * Diagnosed and Treated in China Exclusion Criteria: * Disagreement of involving in this study by the patient or his/her family.
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting -
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China Recruiting -
Third Hospital of Peking University
Beijing, Beijing Municipality, China Recruiting -
Chidren's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China Recruiting -
Shenzhen Children's Hospital
Shenzhen, Guangdong, China Recruiting -
The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI)
Shenzhen, Guangdong, China Recruiting
Show 3 more locations
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China Recruiting -
Children's Hospital of Nanjing Medical University
Nanjing, Jiangsu, China Recruiting -
Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Hongmei Song, MD — Peking Union Medical College Hospital
- Study coordinator: Sihao Gao
- Email: sihao.gao@gmail.com
- Phone: (+86) 010-6915-5727
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Music-4-MS: A 12-week music-based program to support thinking skills in people with MS
A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
Gut microbes and autoinflammatory diseases: how they may be linked
This study tests whether gut bacteria and their byproducts relate to digestive and inflammatory symptoms in people with autoinflammatory diseases.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.